Pfizer Q1 FY26 Earnings Results

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. It is the 3rd largest multinational pharmaceutical company in India. Presenting below are its Q1 FY26 earnings results.

Q1 FY26 Earnings Results

• Revenue from Operations: ₹603 crore, up approximately 7% year-over-year (YoY).

• Net Profit (PAT): ₹191.75 crore, showing a 27% growth compared to previous year.

• Earnings Per Share (EPS): ₹41.91, depicting a 27% growth over the last year.

• EBIT Margin: Strong improvement with reported EBIT at ₹428 crore.

• Total Expenses: Improved significantly to ₹410 Crore as compared to prior quarters, supporting profitability.

• The results reflect steady operational performance and improved profitability for the quarter.

 

Management Commentary & Strategic Highlights

• Pfizer India highlighted continued focus on innovation and operational efficiency driving growth and profitability.

• The company recently launched its 20-valent pneumococcal conjugate vaccine (PCV20) for adults in India, expanding its portfolio in vaccine segments.

• Efforts to maintain a strong product pipeline and market presence remain core strategic priorities.

• Management remains confident in sustaining growth momentum supported by new product launches and expanding healthcare demand domestically.

• Cost control and operational productivity are emphasized to support margin expansion going forward.

 

 

Q4 FY25 Earnings Results

• Pfizer Ltd reported Revenues for Q4FY25 of ₹592.00 Crores up from ₹547.00 Crore year on year, a rise of 8.23%.
• Total Expenses for Q4FY25 of ₹383.00 Crores up from ₹378.00 Crores year on year, a rise of 1.32%.
• Consolidated Net Profit of ₹331.00 Crores up 84.92% from ₹179.00 Crores in the same quarter of the previous year. This was due to boosted by an exceptional gain from a land sale.
• The Earnings per Share is ₹72.34, up 85.01% from ₹39.10 in the same quarter of the previous year.

• EBITDA / EBIT: Margins improved significantly in Q4 FY25, setting a base for Q1 FY26 performance.

• The quarter included one-time exceptional items, though core operations showed healthy profitability.

 

To view the company’s previous earnings and latest concall transcripts, click here  to visit the Alphastreet India news channel.